EU Irritable Bowel Syndrome Treatment Market, by Type (IBS With Diarrhoea, IBS With Constipation, Mixed IBS) and by Product type (Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Other Products) and by Distribution Channel (Drug Stores and Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies) Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138291
- Pages: 200
-
Format:
Report Overview
The EU market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 7.16% during the forecast period
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that you'll need to manage long term. Only a small number of people with IBS have severe signs and symptoms
Market Drivers
UK has one of the largest healthcare systems, the National Health System, in Europe. It aims to create a patient-centric, responsive, and enhanced system, which is set to be beneficial for market growth. According to a review, two in ten people have IBS. The increasing geriatric population contributes to market growth. The aging population is highly vulnerable to diseases like irritable bowel syndrome. Moreover, chronic diseases are becoming a considerable healthcare burden in the Europe. Such factors are assessed to facilitate market growth in the Europe
1. EU Irritable Bowel Syndrome Treatment Market Overview
A. Market Size
2. EU Irritable Bowel Syndrome Treatment Market Growth Drivers
I. Europe aims to create a patient-centric, responsive and enhanced system
II. The increase in geriatric population
III. Aging population and chronic diseases are becoming a considerable healthcare burden in the Europe
3. EU Irritable Bowel Syndrome Treatment Market Segmentation.
A. By Type
I. IBS with diarrhea
II. IBS with constipation
III. Mixed IBS
B. By Product type
I. Rifaximin
II. Eluxadoline
III. Linaclotide
IV. Lubiprostone
V. Other products
C. By Distribution Channel
I. Drug Stores
II. Retail Pharmacies
III. Hospital Pharmacies
IV. Online Pharmacies
4. EU Irritable Bowel Syndrome Treatment Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Novartis AG Company overview, Product & Services, Strategies & Financials
B. Takeda Pharmaceuticals Company overview, Product & Services, Strategies & Financials
C. Constella Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Market Opportunities and Future Trends
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
